These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

111 related articles for article (PubMed ID: 35879478)

  • 1. Absolute treatment effects for the primary outcome and all-cause mortality in the cardiovascular outcome trials of new antidiabetic drugs: a meta-analysis of digitalized individual patient data.
    Kuss O; Akbulut C; Schlesinger S; Georgiev A; Kelm M; Roden M; Wolff G
    Acta Diabetol; 2022 Oct; 59(10):1349-1359. PubMed ID: 35879478
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Meta-analysed numbers needed to treat of novel antidiabetic drugs for cardiovascular outcomes.
    Wolff G; Lin Y; Akbulut C; Brockmeyer M; Parco C; Hoss A; Sokolowski A; Westenfeld R; Kelm M; Roden M; Schlesinger S; Kuss O
    ESC Heart Fail; 2023 Feb; 10(1):552-567. PubMed ID: 36337026
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparative efficacy of novel antidiabetic drugs on cardiovascular and renal outcomes in patients with diabetic kidney disease: A systematic review and network meta-analysis.
    Cao H; Liu T; Wang L; Ji Q
    Diabetes Obes Metab; 2022 Aug; 24(8):1448-1457. PubMed ID: 35665989
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cardiovascular outcomes in trials of new antidiabetic drug classes: a network meta-analysis.
    Fei Y; Tsoi MF; Cheung BMY
    Cardiovasc Diabetol; 2019 Aug; 18(1):112. PubMed ID: 31462224
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Association Between Use of Sodium-Glucose Cotransporter 2 Inhibitors, Glucagon-like Peptide 1 Agonists, and Dipeptidyl Peptidase 4 Inhibitors With All-Cause Mortality in Patients With Type 2 Diabetes: A Systematic Review and Meta-analysis.
    Zheng SL; Roddick AJ; Aghar-Jaffar R; Shun-Shin MJ; Francis D; Oliver N; Meeran K
    JAMA; 2018 Apr; 319(15):1580-1591. PubMed ID: 29677303
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Network Meta-Analysis of Novel Glucose-Lowering Drugs on Risk of Acute Kidney Injury.
    Zhao M; Sun S; Huang Z; Wang T; Tang H
    Clin J Am Soc Nephrol; 2020 Dec; 16(1):70-78. PubMed ID: 33376101
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Network meta-analysis of nine large cardiovascular outcome trials of new antidiabetic drugs.
    Alfayez OM; Al Yami MS; Alshibani M; Fallatah SB; Al Khushaym NM; Alsheikh R; Alkhatib N
    Prim Care Diabetes; 2019 Jun; 13(3):204-211. PubMed ID: 30713085
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Computing and interpreting the Number Needed to Treat for Cardiovascular Outcomes Trials : Perspective on GLP-1 RA and SGLT-2i therapies.
    Ludwig L; Darmon P; Guerci B
    Cardiovasc Diabetol; 2020 May; 19(1):65. PubMed ID: 32404155
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A Systematic Review of Newer Antidiabetic Agents in the Treatment of Nonalcoholic Fatty Liver Disease.
    Dougherty JA; Guirguis E; Thornby KA
    Ann Pharmacother; 2021 Jan; 55(1):65-79. PubMed ID: 32571083
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The effect of DPP-4 inhibitors, GLP-1 receptor agonists and SGLT-2 inhibitors on cardiorenal outcomes: a network meta-analysis of 23 CVOTs.
    Giugliano D; Longo M; Signoriello S; Maiorino MI; Solerte B; Chiodini P; Esposito K
    Cardiovasc Diabetol; 2022 Mar; 21(1):42. PubMed ID: 35296336
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Association between use of sodium-glucose cotransporter 2 inhibitors, glucagon-like peptide 1 agonists, and dipeptidyl peptidase 4 inhibitors with kidney outcomes in patients with type 2 diabetes: A systematic review and network meta-analysis.
    Yang S; He W; Zhao L; Mi Y
    PLoS One; 2022; 17(4):e0267025. PubMed ID: 35421174
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sodium-glucose cotransporter protein-2 (SGLT-2) inhibitors and glucagon-like peptide-1 (GLP-1) receptor agonists for type 2 diabetes: systematic review and network meta-analysis of randomised controlled trials.
    Palmer SC; Tendal B; Mustafa RA; Vandvik PO; Li S; Hao Q; Tunnicliffe D; Ruospo M; Natale P; Saglimbene V; Nicolucci A; Johnson DW; Tonelli M; Rossi MC; Badve SV; Cho Y; Nadeau-Fredette AC; Burke M; Faruque LI; Lloyd A; Ahmad N; Liu Y; Tiv S; Millard T; Gagliardi L; Kolanu N; Barmanray RD; McMorrow R; Raygoza Cortez AK; White H; Chen X; Zhou X; Liu J; Rodríguez AF; González-Colmenero AD; Wang Y; Li L; Sutanto S; Solis RC; Díaz González-Colmenero F; Rodriguez-Gutierrez R; Walsh M; Guyatt G; Strippoli GFM
    BMJ; 2021 Jan; 372():m4573. PubMed ID: 33441402
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Association of Glucagon-Like Peptide-1 Receptor Agonist vs Dipeptidyl Peptidase-4 Inhibitor Use With Mortality Among Patients With Type 2 Diabetes and Advanced Chronic Kidney Disease.
    Chen JJ; Wu CY; Jenq CC; Lee TH; Tsai CY; Tu HT; Huang YT; Yen CL; Yen TH; Chen YC; Tian YC; Yang CW; Yang HY
    JAMA Netw Open; 2022 Mar; 5(3):e221169. PubMed ID: 35254430
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The efficacy and safety of novel classes of glucose-lowering drugs for cardiovascular outcomes: a network meta-analysis of randomised clinical trials.
    Lin DS; Lee JK; Hung CS; Chen WJ
    Diabetologia; 2021 Dec; 64(12):2676-2686. PubMed ID: 34536085
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Improvement of glycemic control and reduction of major cardiovascular events in 18 cardiovascular outcome trials: an updated meta-regression.
    Maiorino MI; Longo M; Scappaticcio L; Bellastella G; Chiodini P; Esposito K; Giugliano D
    Cardiovasc Diabetol; 2021 Oct; 20(1):210. PubMed ID: 34663316
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cost Effectiveness of Sodium-Glucose Cotransporter-2 (SGLT2) Inhibitors, Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists, and Dipeptidyl Peptidase-4 (DPP-4) Inhibitors: A Systematic Review.
    Hong D; Si L; Jiang M; Shao H; Ming WK; Zhao Y; Li Y; Shi L
    Pharmacoeconomics; 2019 Jun; 37(6):777-818. PubMed ID: 30854589
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cardiovascular effects of antidiabetic drugs.
    Sørensen AM; Christensen MB
    Drugs Today (Barc); 2018 Sep; 54(9):547-559. PubMed ID: 30303495
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Insulin and glucose-lowering agents for treating people with diabetes and chronic kidney disease.
    Lo C; Toyama T; Wang Y; Lin J; Hirakawa Y; Jun M; Cass A; Hawley CM; Pilmore H; Badve SV; Perkovic V; Zoungas S
    Cochrane Database Syst Rev; 2018 Sep; 9(9):CD011798. PubMed ID: 30246878
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cardiovascular efficacy and safety of sodium-glucose co-transporter-2 inhibitors and glucagon-like peptide-1 receptor agonists: a systematic review and network meta-analysis.
    Hussein H; Zaccardi F; Khunti K; Seidu S; Davies MJ; Gray LJ
    Diabet Med; 2019 Apr; 36(4):444-452. PubMed ID: 30653708
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of novel glucose lowering agents on non-alcoholic fatty liver disease: A systematic review and meta-analysis.
    Zafar Y; Rashid AM; Siddiqi AK; Ellahi A; Ahmed A; Hussain HU; Ahmed F; Menezes RG; Siddiqi TJ; Maniya MT
    Clin Res Hepatol Gastroenterol; 2022; 46(7):101970. PubMed ID: 35659603
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.